Community pharmacists’ interventions to prevent and screen chronic kidney disease patients. Belaiche, S., Mercier, E., Cuny, D., Kambia, N., Wierre, P., Bertoux, É., Mascaut, D., Azar, R., Bataille, P., Bourdon, F., Mac Namara, É., Maisonneuve, N., Painchart, B., Vrigneau, L., Noël, C., Décaudin, B., & Glowacki, F. Néphrologie & Thérapeutique, 13(2):87–92, April, 2017. ![Community pharmacists’ interventions to prevent and screen chronic kidney disease patients [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Chronic kidney disease (CKD) is a major concern of public health. The pharmacist is known as a health practitioner involved in prevention and therapeutic education. Our study aimed at defining the impact of community pharmacists’ interventions for preventing and screening CKD. In our observational prospective study of 5 months conducted in 109 community pharmacy, we included 2 groups of patients: A (therapeutic optimization): CKD patients and B (CKD screening): population at risk. In group A, we included 354 patients, mainly women (51.2%), in stage 3 of CKD, mean age 73 years old, with hypertension alone (40.6%) or associated with diabetes (44%). About 70% of the patients had a follow up by a nephrologist and 45% of them were good adherent according to the Morisky-Green self-report. However, approximately 20% of patients did not have nephroprotective treatments in their regimen although they were on stage 3 or 4 CKD patients, and about half of them were not aware of medical situations at risk. Concerning group B, 532 patients were included. The pharmaceutical interventions screened 10% of patients with a GFR \textless 60 mL/min/1.73 m2. The community pharmacists’ interventions helped to optimize the therapeutic management of CKD patients and in the early screening of patients at risk. More studies are needed to extrapolate our observations to a larger population.
@article{belaiche_community_2017,
title = {Community pharmacists’ interventions to prevent and screen chronic kidney disease patients},
volume = {13},
issn = {17697255},
url = {http://linkinghub.elsevier.com/retrieve/pii/S1769725516305818},
doi = {10.1016/j.nephro.2016.06.006},
abstract = {Chronic kidney disease (CKD) is a major concern of public health. The pharmacist is known as a health practitioner involved in prevention and therapeutic education. Our study aimed at defining the impact of community pharmacists’ interventions for preventing and screening CKD. In our observational prospective study of 5 months conducted in 109 community pharmacy, we included 2 groups of patients: A (therapeutic optimization): CKD patients and B (CKD screening): population at risk. In group A, we included 354 patients, mainly women (51.2\%), in stage 3 of CKD, mean age 73 years old, with hypertension alone (40.6\%) or associated with diabetes (44\%). About 70\% of the patients had a follow up by a nephrologist and 45\% of them were good adherent according to the Morisky-Green self-report. However, approximately 20\% of patients did not have nephroprotective treatments in their regimen although they were on stage 3 or 4 CKD patients, and about half of them were not aware of medical situations at risk. Concerning group B, 532 patients were included. The pharmaceutical interventions screened 10\% of patients with a GFR {\textless} 60 mL/min/1.73 m2. The community pharmacists’ interventions helped to optimize the therapeutic management of CKD patients and in the early screening of patients at risk. More studies are needed to extrapolate our observations to a larger population.},
language = {fr},
number = {2},
urldate = {2018-07-09TZ},
journal = {Néphrologie \& Thérapeutique},
author = {Belaiche, Stéphanie and Mercier, Edwige and Cuny, Damien and Kambia, Nicolas and Wierre, Patrick and Bertoux, Élisabeth and Mascaut, Daniel and Azar, Raymond and Bataille, Pierre and Bourdon, Franck and Mac Namara, Évelyne and Maisonneuve, Nathalie and Painchart, Bernard and Vrigneau, Laurence and Noël, Christian and Décaudin, Bertrand and Glowacki, François},
month = apr,
year = {2017},
pages = {87--92}
}
Downloads: 0
{"_id":"58cEbWhuFvhSMf4oo","bibbaseid":"belaiche-mercier-cuny-kambia-wierre-bertoux-mascaut-azar-etal-communitypharmacistsinterventionstopreventandscreenchronickidneydiseasepatients-2017","downloads":0,"creationDate":"2019-03-07T14:08:40.434Z","title":"Community pharmacists’ interventions to prevent and screen chronic kidney disease patients","author_short":["Belaiche, S.","Mercier, E.","Cuny, D.","Kambia, N.","Wierre, P.","Bertoux, É.","Mascaut, D.","Azar, R.","Bataille, P.","Bourdon, F.","Mac Namara, É.","Maisonneuve, N.","Painchart, B.","Vrigneau, L.","Noël, C.","Décaudin, B.","Glowacki, F."],"year":2017,"bibtype":"article","biburl":"https://bibbase.org/zotero/Robert Laurine","bibdata":{"bibtype":"article","type":"article","title":"Community pharmacists’ interventions to prevent and screen chronic kidney disease patients","volume":"13","issn":"17697255","url":"http://linkinghub.elsevier.com/retrieve/pii/S1769725516305818","doi":"10.1016/j.nephro.2016.06.006","abstract":"Chronic kidney disease (CKD) is a major concern of public health. The pharmacist is known as a health practitioner involved in prevention and therapeutic education. Our study aimed at defining the impact of community pharmacists’ interventions for preventing and screening CKD. In our observational prospective study of 5 months conducted in 109 community pharmacy, we included 2 groups of patients: A (therapeutic optimization): CKD patients and B (CKD screening): population at risk. In group A, we included 354 patients, mainly women (51.2%), in stage 3 of CKD, mean age 73 years old, with hypertension alone (40.6%) or associated with diabetes (44%). About 70% of the patients had a follow up by a nephrologist and 45% of them were good adherent according to the Morisky-Green self-report. However, approximately 20% of patients did not have nephroprotective treatments in their regimen although they were on stage 3 or 4 CKD patients, and about half of them were not aware of medical situations at risk. Concerning group B, 532 patients were included. The pharmaceutical interventions screened 10% of patients with a GFR \\textless 60 mL/min/1.73 m2. The community pharmacists’ interventions helped to optimize the therapeutic management of CKD patients and in the early screening of patients at risk. More studies are needed to extrapolate our observations to a larger population.","language":"fr","number":"2","urldate":"2018-07-09TZ","journal":"Néphrologie & Thérapeutique","author":[{"propositions":[],"lastnames":["Belaiche"],"firstnames":["Stéphanie"],"suffixes":[]},{"propositions":[],"lastnames":["Mercier"],"firstnames":["Edwige"],"suffixes":[]},{"propositions":[],"lastnames":["Cuny"],"firstnames":["Damien"],"suffixes":[]},{"propositions":[],"lastnames":["Kambia"],"firstnames":["Nicolas"],"suffixes":[]},{"propositions":[],"lastnames":["Wierre"],"firstnames":["Patrick"],"suffixes":[]},{"propositions":[],"lastnames":["Bertoux"],"firstnames":["Élisabeth"],"suffixes":[]},{"propositions":[],"lastnames":["Mascaut"],"firstnames":["Daniel"],"suffixes":[]},{"propositions":[],"lastnames":["Azar"],"firstnames":["Raymond"],"suffixes":[]},{"propositions":[],"lastnames":["Bataille"],"firstnames":["Pierre"],"suffixes":[]},{"propositions":[],"lastnames":["Bourdon"],"firstnames":["Franck"],"suffixes":[]},{"propositions":[],"lastnames":["Mac","Namara"],"firstnames":["Évelyne"],"suffixes":[]},{"propositions":[],"lastnames":["Maisonneuve"],"firstnames":["Nathalie"],"suffixes":[]},{"propositions":[],"lastnames":["Painchart"],"firstnames":["Bernard"],"suffixes":[]},{"propositions":[],"lastnames":["Vrigneau"],"firstnames":["Laurence"],"suffixes":[]},{"propositions":[],"lastnames":["Noël"],"firstnames":["Christian"],"suffixes":[]},{"propositions":[],"lastnames":["Décaudin"],"firstnames":["Bertrand"],"suffixes":[]},{"propositions":[],"lastnames":["Glowacki"],"firstnames":["François"],"suffixes":[]}],"month":"April","year":"2017","pages":"87–92","bibtex":"@article{belaiche_community_2017,\n\ttitle = {Community pharmacists’ interventions to prevent and screen chronic kidney disease patients},\n\tvolume = {13},\n\tissn = {17697255},\n\turl = {http://linkinghub.elsevier.com/retrieve/pii/S1769725516305818},\n\tdoi = {10.1016/j.nephro.2016.06.006},\n\tabstract = {Chronic kidney disease (CKD) is a major concern of public health. The pharmacist is known as a health practitioner involved in prevention and therapeutic education. Our study aimed at defining the impact of community pharmacists’ interventions for preventing and screening CKD. In our observational prospective study of 5 months conducted in 109 community pharmacy, we included 2 groups of patients: A (therapeutic optimization): CKD patients and B (CKD screening): population at risk. In group A, we included 354 patients, mainly women (51.2\\%), in stage 3 of CKD, mean age 73 years old, with hypertension alone (40.6\\%) or associated with diabetes (44\\%). About 70\\% of the patients had a follow up by a nephrologist and 45\\% of them were good adherent according to the Morisky-Green self-report. However, approximately 20\\% of patients did not have nephroprotective treatments in their regimen although they were on stage 3 or 4 CKD patients, and about half of them were not aware of medical situations at risk. Concerning group B, 532 patients were included. The pharmaceutical interventions screened 10\\% of patients with a GFR {\\textless} 60 mL/min/1.73 m2. The community pharmacists’ interventions helped to optimize the therapeutic management of CKD patients and in the early screening of patients at risk. More studies are needed to extrapolate our observations to a larger population.},\n\tlanguage = {fr},\n\tnumber = {2},\n\turldate = {2018-07-09TZ},\n\tjournal = {Néphrologie \\& Thérapeutique},\n\tauthor = {Belaiche, Stéphanie and Mercier, Edwige and Cuny, Damien and Kambia, Nicolas and Wierre, Patrick and Bertoux, Élisabeth and Mascaut, Daniel and Azar, Raymond and Bataille, Pierre and Bourdon, Franck and Mac Namara, Évelyne and Maisonneuve, Nathalie and Painchart, Bernard and Vrigneau, Laurence and Noël, Christian and Décaudin, Bertrand and Glowacki, François},\n\tmonth = apr,\n\tyear = {2017},\n\tpages = {87--92}\n}\n\n","author_short":["Belaiche, S.","Mercier, E.","Cuny, D.","Kambia, N.","Wierre, P.","Bertoux, É.","Mascaut, D.","Azar, R.","Bataille, P.","Bourdon, F.","Mac Namara, É.","Maisonneuve, N.","Painchart, B.","Vrigneau, L.","Noël, C.","Décaudin, B.","Glowacki, F."],"key":"belaiche_community_2017","id":"belaiche_community_2017","bibbaseid":"belaiche-mercier-cuny-kambia-wierre-bertoux-mascaut-azar-etal-communitypharmacistsinterventionstopreventandscreenchronickidneydiseasepatients-2017","role":"author","urls":{"Paper":"http://linkinghub.elsevier.com/retrieve/pii/S1769725516305818"},"downloads":0},"search_terms":["community","pharmacists","interventions","prevent","screen","chronic","kidney","disease","patients","belaiche","mercier","cuny","kambia","wierre","bertoux","mascaut","azar","bataille","bourdon","mac namara","maisonneuve","painchart","vrigneau","noël","décaudin","glowacki"],"keywords":[],"authorIDs":[],"dataSources":["yP2f7ZTqzqGzG39kW"]}